Vicagrel is under clinical development by Jiangsu Vcare PharmaTech and currently in Pre-Registration for Ischemic Stroke. According to GlobalData, Pre-Registration drugs for Ischemic Stroke have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Vicagrel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vicagrel overview

Vicagrel was under investigation for the treatment of the acute coronary syndrome, ischaemic stroke, and peripheral arterial disease. It was administered through the oral route as a capsule and suspension. It acts by targeting the ADP glucose receptor.

Jiangsu Vcare PharmaTech overview

Jiangsu Vcare PharmaTech is a Pharmaceuticals and Healthcare company that provides Medicine Manufacturing services. The company is Headquartered in Nanjing, Jiangsu, China.

For a complete picture of Vicagrel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.